Transcatheter tricuspid valve replacement update: a company press release previews an ambitious clinical study and the investigators guiding its rollout.
Key Takeaways
- Pivotal randomized trial targets about 400 patients randomized two-to-one against commercial devices
- Up to 150 additional patients will join a single-arm registry for ineligible cases
- Three global principal investigators were named from major US structural heart centers